Psychedelics
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
Revive Therapeutics Ltd. (“Revive”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously announced bought deal prospectus offering of 46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross […]
February 12, 2021 09:08 AM Eastern Standard Time DENVER–(BUSINESS WIRE)–Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce the closing of its previously-announced bought-deal public offering […]
Delic’s First Acquisition in Bid to Become Psychedelic Clinic Leader
The psychedelics industry is projected to reach nearly $7 billion by 2027, according to Data Bridge Market Research, representing a 16.3% compound annual growth rate. Most companies in the space are undergoing expensive preclinical and clinical trials to bring psilocybin and other psychedelics to market and treat unmet medical needs in mental health. While psilocybin […]
CaaMTech’s first of over one hundred patent applications is nearing the finish line
ISSAQUAH, Wash., Feb. 10, 2021 /PRNewswire/ — CaaMTech, Inc., announced today that its first patent application, “Compositions and methods comprising a psilocybin derivative” (US20180221396A1), has been allowed by the US Patent and Trademark Office (USPTO). The notice of allowance is a watershed moment for CaaMTech’s intellectual property division, which has filed in excess of one hundred additional patent applications […]
Core One Labs Highlights Key Points from International Investor Call
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (“Core One”) is pleased with the tremendous turnout on the International Investors’ Call held earlier today. Core One’s Chairman, Dr. Robert E.W. Hancock and Chief Executive Officer, Joel Shacker provided participants an update on the Company’s current Intellectual Property and patent application process, cost to produce psilocybin, […]
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial
Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders. In addition, Cedar Clinical Research […]
Nova Mentis Appoints Gary R. Harlem to Scientific Advisory Board
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA”), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that it has appointed Gary R. Harlem to its Scientific Advisory Board, effective immediately. Mr. Harlem is the founder and CEO of Altucell Biotech, a cellular engineering and biotech company […]
MINDCURE Announces Listing of Warrants
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) is pleased to announce that the Canadian Securities Exchange (CSE) has accepted for listing the 38,334,100 units issued pursuant to the Company’s previously announced prospectus offering that closed Feb. 10, 2021. Each warrant entitles the holder to acquire one common share […]
Cybin to Provide Business Update on February 17, 2021 Conference Call
Cybin Inc. (NEO:CYBN) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will conduct a conference call and webcast to review its financial results and provide a business update as follows: DateWednesday, February 17, 2021 Time: 10:00AM ET Toll Free: (U.S.) (877) 407-0789 International: (201) 689-8562 Conference […]
PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke
Toronto, Ontario–(Newsfile Corp. – February 11, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has filed an application with the U.S. Food and […]
Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor
La Jolla, California–(Newsfile Corp. – February 11, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp” or the “Company”) a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has executed an advisory agreement with Dr. Joel Castellanos, a noted chronic pain physician at UC San Diego […]
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (“Mindset“), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that several of its proprietary, novel and diverse psychedelic compounds are demonstrating strong potency and efficacy, superior to psilocybin in in vivo proof-of-concept (“PoC“) studies. These PoC […]
Psyence Group Inc., through its wholly-owned subsidiary Psyence Therapeutics Corp. (“Psyence”), is pleased to announce it has entered into a Research Collaboration Agreement with MycoMeditations Inc (“MycoMeditations”), a leading psilocybin retreat provider to conduct an observational study of the efficacy of naturally derived psilocybin. The Psyence Group is a leading platform in naturally derived psychedelic […]
Field Trip Health Ltd. (CSE: FTRP, FTRP.WT, OTCQX: FTRPF) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its third fiscal quarter ended December 31, 2020, after market close on Tuesday, February 16, 2021. The Company will conduct a conference call […]
Mind Cure Health Inc. (“Mind Cure” or the “Company”) (CSE: MCUR), a mental health and wellness company with a mission to identify and develop products that ease suffering, increase productivity, and enhance mental health, is pleased to announce that it has closed its previously announced bought deal short form prospectus public offering (the “Offering”) of […]
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has expanded its Discovery Center, through collaborations with world-leading laboratories at UC San Diego, School of Medicine, and Medical College of Wisconsin (MCW). Adam Halberstadt PhD, Associate Professor, Psychiatry, […]
Nova Mentis Psilocybin Approved for Shipment to Italy
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA”) is pleased to announce that its proprietary drug psilocybin has been shipped to the laboratory of Dr. Viviana Trezza, Roma Tre University, Rome, Italy. NOVA was notified by its U.S. drug manufacturer that the required controlled substances export application had been approved by […]
Revive Therapeutics Ltd. (“Revive”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that, further to its press releases dated January 20, 2021 and January 21, 2021, the Company has received a receipt for its final short form […]
Mydecine Innovations Group Files Final Prospectus in Connection with Bought Deal Offering of Units
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that, in connection with its bought deal offering (the “Offering”) previously announced on January 14, 2021, it has filed its […]
Vancouver, British Columbia–(Newsfile Corp. – February 10, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (“NeonMind“), announces that through its consumer products division, it submitted on February 2, 2021 four applications to Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD), to obtain product licenses for its products with 100% plant-based extracts, and make their related health […]
Silo Pharma to pursue additional strategic partnerships and intellectual property acquisitions in the psychedelic medicine space Englewood Cliffs, NJ, Feb. 10, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other […]
The laboratory, which is the first facility dedicated exclusively to the study of plant-based psychedelics, is being launched in partnership with University of the West Indies TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“FieldTrip“), a leader in the development and delivery of psychedelic therapies, is pleased […]
Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller
La Jolla, California–(Newsfile Corp. – February 8, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp”), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announces it has commenced a collaboration with Dr. Jennifer Miller of the University of Florida as the Principal Investigator for a clinical […]
PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that is has appointed world-renowned chemist and neuroscientist Dr. Steven A. Barker, Ph.D. to the Company’s newly-formed scientific advisory […]
Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing
Numinus Wellness Inc. (“Numinus” ) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), has closed its acquisition of Mindspace Psychology Services Inc. (DBA Mindspace Wellbeing), a leader and pioneer in psychedelic programming. The purchase agreement was previously announced on […]
GHP Noetic Science-Psychedelic Pharma Inc. (TSXV:PSYF.P) (“GHP“), a capital pool company, and Diamond Therapeutics Inc. (“Diamond“), a psychedelic drug development company focused on low-dose therapies for mental health, are pleased to announce the signing of a letter of intent dated effective February 2, 2021 (the “LOI“). The LOI sets out the general terms and conditions […]
Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) announces that it has engaged Donohoe Advisory Associates LLC (“Donohoe Advisory”) in connection with its efforts to seek a listing for its common shares on a NASDAQ Stock Market. The Company expects that listing its common shares on NASDAQ will provide increased investor […]
Bright Minds Biosciences Announces Listing on Canadian Stock Exchange
VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders, today announced that the Company’s common shares (the “Shares”) are expected to commence […]
Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds
Toronto, Ontario–(Newsfile Corp. – February 5, 2021) – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (“Mindset” or the “Company“), a leading drug discovery and development company focused on the development novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce that the Company has filed 3 final patent applications with the U.S. Patent and Trademark […]
Tryp Therapeutics Announces Strategic Investment of $2,000,000
La Jolla, California–(Newsfile Corp. – February 5, 2021) – Tryp Therapeutics Inc. (CSE: TRYP) (“Tryp“) is pleased to announce a non-brokered private placement (the “Placement“) of 3,333,333 million units (the “Units“) at a price of $0.60 per Unit, to raise gross proceeds of approximately $2.0 million. Marc Lustig, founder and former Chairman of Origin House […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
Weekend Unlimited aggregates and scales small to medium cannabis brands in flower, extracts, and edibles.
Rubicon Holdings, Inc., a Washington State corporation, is a cannabis company focused on the United States adult use and medical marijuana markets.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
